The number of pharmacy supply disruptions lasting at least a week has almost doubled since the start of the year. One pharmacist fears that the situation will worsen.
The AHA calls for individualizing PAD care through patient-reported outcome measures and developing metrics to ensure high-quality care that could be tied to reimbursement.
Single-dose gene therapy, betibeglogene autotemcel, may represent a cure for most with beta-thalassemia, but it costs a record-high $2.8 million. Details on how coverage will work remain murky
Private Medicare Advantage health plans are increasingly ending coverage for skilled nursing or rehab services before medical providers think patients are healthy enough to go home.
DBS is safe and effective for treatment-resistant obsessive–compulsive disorder that can be expected to produce significant clinical benefit in about 2 out of 3 cases, but insurance rarely pays.